|
|
|
|
|
by rustyhancock
58 days ago
|
|
Agreed, especially in some subpopulations. I think the strong case today is to research it's use in people with Dawn's syndrome (accelerated development Alzheimer's Disease due to 3 copies of the APP gene). Target it only to people with those 3 copies. It's legimate as people with DS have a hugely increased risk of AD.
Their risk increase seems likely related specifically to Amyloid.
Many with DS can consent to it. In general my completely gut feeling is that once we can target Tau we might find that targeting amyloid is needed to fully curtail progression. |
|
Trials are currently ongoing. The results should start trickling out in a few years...